182 results
Page 3 of 10
8-K
EX-10.1
98405j
22 Mar 22
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
4:06pm
424B3
0uoxp
19 Jan 22
Prospectus supplement
4:05pm
8-K
EX-4.1
lkia60
4 Jan 22
Entry into a Material Definitive Agreement
6:02am
8-K
6digj
10 Sep 21
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
EX-10.1
cz0shybq8r0m3v3ivhmt
14 Jun 21
Entry into a Material Definitive Agreement
4:08pm
8-K
EX-99.2
qgs bwxj742b1
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.2
3ml3v
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
S-8
vj22i
17 Mar 21
Registration of securities for employees
4:06pm
S-8
EX-23.1
0kcyw hbyri
17 Mar 21
Registration of securities for employees
4:06pm
8-K
EX-99.1
b8soikiy s2e1
2 Mar 21
Regulation FD Disclosure
8:00am
8-K
EX-10.1
k8qbdkh9e9zb7crtcf3
16 Feb 21
Entry into a Material Definitive Agreement
7:10am
424B5
xdubn4
16 Feb 21
Prospectus supplement for primary offering
7:05am
8-K
EX-10.1
wpc5t3nwfs2q
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm